Earnings Feed
Start Free
Apellis Pharmaceuticals, Inc.·4

Jan 23, 4:08 PM ET

Nicholson Nur 4

Research Summary

AI-generated summary

Updated

Apellis (APLS) CTO Nicholson Nur Sells 7,725 Shares

What Happened
Nicholson Nur, Chief Technical Officer of Apellis Pharmaceuticals (APLS), sold 7,725 shares on January 22, 2026 at $21.77 per share, generating proceeds of $168,138. The Form 4 reports this transaction as a sale (S) and the filing notes the shares were sold to cover tax withholding on Restricted Stock Units that vested on January 21, 2026.

Key Details

  • Transaction date and price: 2026-01-22 — 7,725 shares @ $21.77 per share.
  • Total proceeds: $168,138 (gross).
  • Reason given (footnote F1): Shares sold to cover tax withholding on RSUs released Jan 21, 2026.
  • Filing date / timeliness: Report filed 2026-01-23 (filed the next day; within the Form 4 reporting window).
  • Shares owned after transaction: Not specified in the provided filing excerpt.

Context
This was a tax-withholding sale tied to RSU vesting, a common and typically routine transaction for executives and not necessarily a signal about the insider's view of the company. Purchases or large, unscheduled sales can be more informative about insider sentiment; this transaction appears administrative in nature.